# A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis

> **NCT00784693** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 48 (actual)

## Conditions studied

- Endometriosis

## Interventions

- **BIOLOGICAL:** Tanezumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00784693
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12-18
- **Primary completion:** 2010-01-27
- **Final completion:** 2010-04-05
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Further recruitment into the study was ceased on 10th December 2009, not attributed to safety. All patients recruited in the study completed all study visits.
- **Last updated:** 2021-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00784693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00784693, "A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00784693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*